{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:31:51Z","timestamp":1774999911669,"version":"3.50.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.beha.2021.101305","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T05:43:46Z","timestamp":1630043026000},"page":"101305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8405-1141","authenticated-orcid":false,"given":"Vanessa A.","family":"Fabrizio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-9956","authenticated-orcid":false,"given":"Kevin J.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.beha.2021.101305_bib1","first-page":"7","article-title":"Cancer statistics","volume":"67","author":"Siegel","year":"2017","journal-title":"CA A Cancer J Clin"},{"issue":"14","key":"10.1016\/j.beha.2021.101305_bib2","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.beha.2021.101305_bib3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2021.101305_bib4","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.beha.2021.101305_bib5","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.beha.2021.101305_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2005.05773.x","article-title":"Childhood acute lymphoblastic leukaemia and relapse","volume":"131","author":"Gaynon","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2021.101305_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2010.09.020","article-title":"Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group","volume":"47","author":"von Stackelberg","year":"2011","journal-title":"Eur J Canc"},{"issue":"24","key":"10.1016\/j.beha.2021.101305_bib8","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1002\/cncr.25354","article-title":"Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.beha.2021.101305_bib9","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2021.101305_bib10","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2021.101305_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjh.12358","article-title":"Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation","volume":"162","author":"Campana","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2021.101305_bib12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1186\/s12885-018-4670-5","article-title":"Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis","volume":"18","author":"Shen","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.beha.2021.101305_bib13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/bmt.2012.139","article-title":"Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia","volume":"48","author":"Buckley","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.beha.2021.101305_bib14","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"224","key":"10.1016\/j.beha.2021.101305_bib15","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.beha.2021.101305_bib16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"9967","key":"10.1016\/j.beha.2021.101305_bib17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beha.2021.101305_bib18","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"25","key":"10.1016\/j.beha.2021.101305_bib19","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2021.101305_bib20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"The New England journal of medicine"},{"issue":"5","key":"10.1016\/j.beha.2021.101305_bib21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.beha.2021.101305_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and Response following CD19-specific CAR T cells in pediatric\/young adult relapsed\/refractory B-ALL","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101305_bib23","first-page":"JCO1901892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","author":"Frey","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2021.101305_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1084\/jem.102.2.157","article-title":"Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer","volume":"102","author":"Mitchison","year":"1955","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.beha.2021.101305_bib25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.beha.2021.101305_bib26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/14653240701650320","article-title":"Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials","volume":"9","author":"DiGiusto","year":"2007","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.beha.2021.101305_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","article-title":"Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy","volume":"32","author":"Hollyman","year":"2009","journal-title":"J Immunother"},{"issue":"3","key":"10.1016\/j.beha.2021.101305_bib28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/CJI.0b013e3181c0c3cb","article-title":"Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex)","volume":"33","author":"Vera","year":"2010","journal-title":"J Immunother"},{"issue":"3","key":"10.1016\/j.beha.2021.101305_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CJI.0b013e31824e801f","article-title":"Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment","volume":"35","author":"Jin","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.beha.2021.101305_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1479-5876-10-69","article-title":"Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE(R) bioreactor","volume":"10","author":"Somerville","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.beha.2021.101305_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40425-015-0049-1","article-title":"Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application","volume":"3","author":"Sun","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"15","key":"10.1016\/j.beha.2021.101305_bib32","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2021.101305_bib33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jgm.2604","article-title":"Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions","volume":"14","author":"Curran","year":"2012","journal-title":"J Gene Med"},{"issue":"20 Pt 1","key":"10.1016\/j.beha.2021.101305_bib34","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Canc Res"},{"issue":"4","key":"10.1016\/j.beha.2021.101305_bib35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Canc Discov"},{"issue":"18 Pt 1","key":"10.1016\/j.beha.2021.101305_bib36","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin Canc Res"},{"issue":"4","key":"10.1016\/j.beha.2021.101305_bib37","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2021.101305_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Canc"},{"issue":"8","key":"10.1016\/j.beha.2021.101305_bib39","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1517\/14712598.7.8.1207","article-title":"T-cell receptor gene therapy for cancer: the progress to date and future objectives","volume":"7","author":"Thomas","year":"2007","journal-title":"Expet Opin Biol Ther"},{"issue":"11","key":"10.1016\/j.beha.2021.101305_bib40","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1089\/104303403322124800","article-title":"Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells","volume":"14","author":"Zhou","year":"2003","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.beha.2021.101305_bib41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2003-01-0297","article-title":"Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence","volume":"102","author":"Cavalieri","year":"2003","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2021.101305_bib42","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-all","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2021.101305_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.beha.2021.101305_bib44","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2021.101305_bib45","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.beha.2021.101305_bib46","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2021.101305_bib47","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.beha.2021.101305_bib48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.beha.2021.101305_bib49","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101305_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-136340","article-title":"HESTER: a phase II study evaluating efficacy and safety of tisagenlecleucel reinfusion in pediatric and young adult patients with acute lymphoblastic leukemia experiencing loss of B-cell aplasia","volume":"136","author":"Boyer","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101305_bib51","first-page":"JCO2003458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.beha.2021.101305_bib52","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2016.34.15_suppl.3007","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2021.101305_bib53","article-title":"Artificial antigen presenting cells: an off the shelf approach for generation of desirable T-cell populations for broad application of adoptive immunotherapy","volume":"4","author":"Hasan","year":"2015","journal-title":"Adv Genet Eng"},{"issue":"4","key":"10.1016\/j.beha.2021.101305_bib54","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/PPO.0b013e3181eb33a6","article-title":"Artificial antigen-presenting cells for use in adoptive immunotherapy","volume":"16","author":"Turtle","year":"2010","journal-title":"Cancer J"},{"issue":"12","key":"10.1016\/j.beha.2021.101305_bib55","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Canc Discov"},{"issue":"5","key":"10.1016\/j.beha.2021.101305_bib56","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-all patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.beha.2021.101305_bib57","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"issue":"22","key":"10.1016\/j.beha.2021.101305_bib58","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.beha.2021.101305_bib59","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101305_bib60","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.beha.2021.101305_bib61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2021.101305_bib62","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00007890-199004000-00009","article-title":"In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids","volume":"49","author":"Chatenoud","year":"1990","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.beha.2021.101305_bib63","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1172\/JCI119110","article-title":"Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a\/CD18 (LFA-1) on NK cells","volume":"98","author":"Wing","year":"1996","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.beha.2021.101305_bib64","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2021.101305_bib65","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"The New England journal of medicine"},{"issue":"1","key":"10.1016\/j.beha.2021.101305_bib66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1479-5876-2-17","article-title":"Forecasting the cytokine storm following systemic interleukin (IL)-2 administration","volume":"2","author":"Panelli","year":"2004","journal-title":"J Transl Med"},{"issue":"26","key":"10.1016\/j.beha.2021.101305_bib67","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2021.101305_bib68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"issue":"1","key":"10.1016\/j.beha.2021.101305_bib69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2021.101305_bib70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.beha.2021.101305_bib71","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.beha.2021.101305_bib72","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Canc Discov"},{"issue":"1","key":"10.1016\/j.beha.2021.101305_bib73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2021.101305_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.beha.2021.101305_bib75","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.beha.2021.101305_bib76","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2021.101305_bib77","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Canc Discov"},{"issue":"12","key":"10.1016\/j.beha.2021.101305_bib78","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Canc Discov"},{"issue":"1","key":"10.1016\/j.beha.2021.101305_bib79","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1158\/2159-8290.CD-NB2017-169","article-title":"JCAR015 in all: a root-cause investigation","volume":"8","year":"2018","journal-title":"Canc Discov"},{"issue":"9","key":"10.1016\/j.beha.2021.101305_bib80","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1177\/1060028015588555","article-title":"Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia","volume":"49","author":"Buie","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.beha.2021.101305_bib81","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.beha.2021.101305_bib82","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2021.101305_bib83","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101305_bib84","unstructured":"V.2.2021 NGfMoI-RT."},{"key":"10.1016\/j.beha.2021.101305_bib85","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"Sandler","year":"2020","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.beha.2021.101305_bib86","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2021.101305_bib87","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"issue":"32","key":"10.1016\/j.beha.2021.101305_bib88","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"355","key":"10.1016\/j.beha.2021.101305_bib89","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.beha.2021.101305_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/S1465324921002899","article-title":"Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from the pediatric real-world car consortium","volume":"23","author":"Curran","year":"2021","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.beha.2021.101305_bib91","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1182\/blood-2005-12-4942","volume":"107","author":"Eapen","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2021.101305_bib92","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3324\/haematol.12291","article-title":"Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time","volume":"93","author":"Balduzzi","year":"2008","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.beha.2021.101305_bib93","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbmt.2011.12.585","article-title":"Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review","volume":"18","author":"Oliansky","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.beha.2021.101305_bib94","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.bbmt.2014.02.021","article-title":"Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia","volume":"20","author":"Wood","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.beha.2021.101305_bib95","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","article-title":"Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial","volume":"33","author":"Peters","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2021.101305_bib96","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.beha.2021.101305_bib97","first-page":"825","article-title":"Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.beha.2021.101305_bib98","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"10.1016\/j.beha.2021.101305_bib99","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2021.101305_bib100","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.beha.2021.101305_bib101","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41409-020-0926-1","article-title":"Low toxicity and favorable overall survival in relapsed\/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant","volume":"55","author":"Fabrizio","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.beha.2021.101305_bib102","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1016\/j.beha.2021.101305_bib103","article-title":"Potential utility of minimal residual disease (MRD) to identify relapse in pediatric and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients treated with tisagenlecleucel","volume":"79","author":"Pulsipher","year":"2019","journal-title":"Canc Res"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:07:02Z","timestamp":1761498422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692621000700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1521692621000700"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2021.101305","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2021.101305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101305"}}